A detailed history of Captrust Financial Advisors transactions in Genmab A/S stock. As of the latest transaction made, Captrust Financial Advisors holds 44,850 shares of GMAB stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,850
Previous 46,303 3.14%
Holding current value
$1.01 Million
Previous $1.38 Million 18.57%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$25.13 - $30.27 $36,513 - $43,982
-1,453 Reduced 3.14%
44,850 $1.13 Million
Q1 2024

May 15, 2024

BUY
$26.43 - $32.77 $184,032 - $228,177
6,963 Added 17.7%
46,303 $1.38 Million
Q4 2023

Feb 14, 2024

SELL
$27.94 - $35.44 $140,398 - $178,086
-5,025 Reduced 11.33%
39,340 $1.25 Million
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $1.37 Million - $1.64 Million
38,797 Added 696.79%
44,365 $1.56 Million
Q2 2023

Aug 14, 2023

SELL
$37.4 - $42.94 $19,448 - $22,328
-520 Reduced 8.54%
5,568 $211,000
Q1 2023

May 15, 2023

SELL
$34.88 - $43.22 $45,448 - $56,315
-1,303 Reduced 17.63%
6,088 $229,000
Q4 2022

Feb 15, 2023

BUY
$33.8 - $47.06 $249,815 - $347,820
7,391 New
7,391 $313,000
Q2 2022

Aug 23, 2022

SELL
$26.83 - $38.57 $38,903 - $55,926
-1,450 Reduced 37.26%
2,442 $79,000
Q2 2022

Aug 16, 2022

BUY
$26.83 - $38.57 $33,108 - $47,595
1,234 Added 46.43%
3,892 $126,000
Q1 2022

May 16, 2022

BUY
$30.95 - $39.68 $31,476 - $40,354
1,017 Added 61.97%
2,658 $96,000
Q4 2021

Feb 14, 2022

BUY
$35.87 - $47.12 $8,142 - $10,696
227 Added 16.05%
1,641 $65,000
Q3 2021

Nov 16, 2021

BUY
$41.55 - $48.72 $11,052 - $12,959
266 Added 23.17%
1,414 $62,000
Q2 2021

Aug 16, 2021

BUY
$32.88 - $44.57 $2,959 - $4,011
90 Added 8.51%
1,148 $47,000
Q1 2021

May 17, 2021

BUY
$30.92 - $44.4 $20,345 - $29,215
658 Added 164.5%
1,058 $35,000
Q3 2020

Nov 17, 2020

BUY
$33.07 - $38.68 $13,228 - $15,472
400 New
400 $15,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.8B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.